Author | Gonçalves, Gustavo | |
Author | Campos, Monique Paiva de | |
Author | Gonçalves, Alessandra Silva | |
Author | Figueiredo, Fabiano Borges | |
Access date | 2024-03-14T19:24:19Z | |
Available date | 2024-03-14T19:24:19Z | |
Document date | 2023 | |
Citation | GONÇALVES, Gustavo et al. Therapeutic success and failure in using miltefosine to treat dogs naturally infected with Leishmania infantum. Revista Brasileira de Parasitologia Veterinária., v. 33, n. 1, p. 1-7, 2024. | en_US |
ISSN | 1983-0246 | en_US |
URI | https://www.arca.fiocruz.br/handle/icict/63075 | |
Language | por | en_US |
Publisher | Associação Brasileira de Patologia Veterinária | en_US |
Rights | open access | en_US |
Title | Therapeutic success and failure in using miltefosine to treat dogs naturally infected with Leishmania infantum | en_US |
Type | Article | en_US |
Abstract | Extended-spectrum beta-lactamase producing and ciprofloxacin-non-susceptible Escherichia coli are clinical and environmental issues. We evaluated the susceptibility profile of fosfomycin in non-susceptible E. coli isolated from urine and the environment. We measured the activity of fosfomycin against 319 and 36 E. coli strains from urine and environmental isolates, respectively, collected from rivers. Fosfomycin resistance profiles were investigated using the minimal inhibitory concentration (MIC), according to the Clinical and Laboratory Standards Institute (CLSI) and the European Committee for Antimicrobial Susceptibility Testing (EUCAST) guidelines. Antibiotic susceptibility testing revealed that 5% and 6.6% of urine samples were non-susceptible to fosfomycin according to CLSI and EUCAST guidelines, respectively. The fosfomycin MIC50/90 was 0.5/4 mg/L. Of the 36 E. coli isolates from river water, 11.1% and 13,8% were non-susceptible to fosfomycin according to CLSI and EUCAST, respectively (range ≤0.25 ≥512 mg/L). All the isolates with MIC ≥512 mg/L for fosfomycin showed the fosA3 gene. Fosfomycin resistance was more
frequent in the environment than in clinical samples. | en_US |
Affilliation | Fundação Oswaldo Cruz. Instituto Carlos Chagas. Laboratório de Biologia Celular. Curitiba, PR, Brasil. | en_US |
Affilliation | Fundação Oswaldo Cruz. Instituto Carlos Chagas. Laboratório de Referência em Leishmaniase. Curitiba, PR, Brasil. | en_US |
Affilliation | Pesquisadora independente. Campo Grande, MS, Brasil. | en_US |
Affilliation | Fundação Oswaldo Cruz. Instituto Carlos Chagas. Laboratório de Referência em Leishmaniase. Curitiba, PR, Brasil. | en_US |
Subject | Leishmaniasis, Visceral | en_US |
Subject | drug therapy | en_US |
Subject | Parasitic Load | en_US |
Subject in Spanish | Leishmaniasis Visceral | en_US |
Subject in Spanish | tratamiento farmacológico | en_US |
Subject in French | Leishmaniose viscérale | en_US |
Subject in French | Leishmaniose viscérale | en_US |
DeCS | Leishmaniose Visceral Canina | en_US |
DeCS | tratamento farmacológico | en_US |
DeCS | Carga Parasitária | en_US |
DeCS | Phlebotomus | en_US |